Platino-resistance in Ovarian Cancer (PlatinOv)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03954171|
Recruitment Status : Not yet recruiting
First Posted : May 17, 2019
Last Update Posted : May 17, 2019
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).
Patients will receive treatment (platinum based-chemotherapy) according to the standard practices.
A prospective database and an associated biological collection will be performed during 5 years:
- For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care.
- Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study).
Study participation of each patient will be 5 years.
|Condition or disease||Intervention/treatment||Phase|
|Epithelial Ovarian Cancer||Other: Patients treated with platinum based-chemotherapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||600 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Platino-resistance in Ovarian Cancer|
|Estimated Study Start Date :||May 2019|
|Estimated Primary Completion Date :||May 2029|
|Estimated Study Completion Date :||May 2029|
|Patients treated with platinum based-chemotherapy||
Other: Patients treated with platinum based-chemotherapy
Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):
If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.
- The rate of patients alive without progression [ Time Frame: 5 years for each patient ]
- The time to onset of platinum based-chemotherapy resistance [ Time Frame: 5 years for each patient ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03954171
|Contact: Gwenaël FERRON||05 31 15 53 55||Ferron.Gwenael@iuct-oncopole.fr|
|Institut Universitaire du Cancer de Toulouse - Oncopole||Not yet recruiting|
|Contact: Gwenaël FERRON 05 31 15 53 55 Ferron.Gwenael@iuct-oncopole.fr|